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The link between renal sodium excretion and body fluid volumes has been a topic of interest since
the early days of renal physiology (1). Glomerular filtration rate (GFR) and aldosterone were the
first two controllers of renal sodium excretion to be recognized. A “third factor” was discovered
when de Wardener and colleagues showed that volume expansion natriuresis still occurred in dogs
given supramaximal doses of mineralocorticoids and without an increase in GFR (2). de Wardener
et al. suggested that the natriuresis was due to a “natriuretic hormone” (NH), launching a new field
of investigation. NH was thus defined as a compound that circulates in blood, the level of which is
regulated appropriately by changes in sodium and water balance.
The nine chapters that follow highlight several areas in which the NH field has subsequently
developed. First, de Wardener’s original experiments were refined to control potential factors
other than GFR and aldosterone. These studies, reviewed by Lichardus (3), confirmed the original
observation, and also led to the discovery of the so-called “physical factors” that affect sodium
excretion (4). Second, attempts to purify NH from various tissues and body fluids, as summarized
in Table 1 by Hamlyn (5), led to the discovery of two important families of factors, atrial natriuretic
peptides (ANP), and endogenous cardiotonic steroids (CTS).
The discovery of ANP led rapidly to its characterization as a family of peptides with three major
components: ANP derived from cardiac tissue, BNP from brain, and CNP from endothelium (6).
This complex system of natriuretic vasodilators, discussed in the chapters byHamlyn (5), andHodes
and Lichstein (6), continues to be of interest as anNH, a neurotransmitter (6), and a factorwithmany
other functions (7).
In sharp contrast, the identification of endogenous CTS as circulatingNa, KATPase inhibitors has
been the source of considerable controversy (8). Two structural classes of CTS have been identified:
authentic ouabain, and the bufodienolides, originally identified in toads (9). As discussed by Ham-
lyn, a bufodienolide is the more likely candidate NH, whereas ouabain in physiologic concentration
appears to be antinatriuretic (5). CTS cause vasoconstriction by amechanism proposed by Blaustein
et al. (10) and endogenous CTS have been implicated in the pathophysiology of hypertension (9).
Despite overwhelming evidence to the contrary, however, difficulty identifying ouabain in biological
fluids continues to be reported (11, 12).
At least three other natriuretic compounds related to control of sodium balance have been
identified. As discussed by Gonick (13), a natriuretic protein associated with various forms of
human hypertension consists of a 408Da compound and a 12 kDa carrier protein. The identity
of these compounds has not been completed (see below). Two xanthurenic acid derivatives (MW
368 and 284), discussed by Bricker et al. (14), are potential regulators of sodium balance in
chronic renal failure. Dietary sodium releases two natriuretic factors from the gastrointestinal tract
identified as guanylin and uroguanylin (MW 10.3 and 1.7 kDa), discussed in the paper by Hodes
and Lichstein (6).
Two other types of natriuretic compounds that inhibit Na, K ATPase, but are not natriuretic hor-
mones as defined above, are two vanadiumdiascorbates (MWapproximately 400), and two spherical
oligo silicic acids (SOSA) (MW 408). These interesting compounds of uncertain significance are
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described in papers by their discoverers Kramer (15) and Kerek
and Voicu (16), respectively. The apparent identical molecular
weight of SOSA and the compound isolated by Gonick is possibly
a coincidence. Alternatively, it may be related to the trace amounts
of silicon in human plasma (17) and have significance beyond that
implied by the serendipitous discovery of SOSA.
A third area is studies of the physiological mechanism(s) by
which these factors might function as natriuretic hormones. ANP
release is controlled by stretch of the cardiac atria (18), and in
that regard is a classic, volume controlled, NH system as originally
conceived (19). Although evidence indicates that CTS are released
in response to increased sodium intake (5), no causal mechanism
connecting sodium intake and CTS release has been demon-
strated. As noted by Hamlyn (5), cerebrospinal fluid sodium
concentration controls the release of an unidentified natriuretic
factor from brain, causing “CNS natriuresis.” The possible role of
CTS or some other NH in this phenomenon should be explored.
A fourth area of investigation is studies of collateral, patho-
physiological, effects of the various factors. Both ANP and CTS
are vasoactive and have been implicated in the pathophysiology of
hypertension (5, 6, 9). Since both appear to be neurotransmitters
or neuromodulators (6), their role in hypertension may have both
central and peripheral components. Pathological effects of excess
CTS in the CNS may also include an etiologic role in mood
disorders, including depression and bipolar disorder (6).
Finally, the signaling effects of CTS on Na, K ATPase not
dependent on ion pumping, mediated by activation of the tyrosine
kinase Src and other signaling molecules, is discussed by Xie et al.
(20). This pathway is involved in the natriuretic effect of bufo-
dienolides (21), and is implicated in pathophysiological processes,
such as oxidative stress, and organ fibrosis (20).
de Wardener’s original hypothesis has led to the discovery of
a rich array of factors with multiple biologic activities. ANP is
the only classical NH described so far. Future work, including the
development of methods for antagonizing these factors, should
increase our understanding of the regulation of renal sodium
excretion and blood pressure and offer novel treatments for sev-
eral clinical disorders.
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